

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/M95396F7824EN.html>

Date: December 2019

Pages: 2062

Price: US\$ 2,500.00 (Single User License)

ID: M95396F7824EN

Abstracts

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key

players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 10, 103, 107, 1, 11, 159, 29 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 13, 18, 5, 31 and 8 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).

The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler

Disease) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Multiple Myeloma (Kahler Disease) - Overview

Multiple Myeloma (Kahler Disease) - Therapeutics Development

Multiple Myeloma (Kahler Disease) - Therapeutics Assessment

Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development

Multiple Myeloma (Kahler Disease) - Drug Profiles

Multiple Myeloma (Kahler Disease) - Dormant Projects

Multiple Myeloma (Kahler Disease) - Discontinued Products

Multiple Myeloma (Kahler Disease) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Aadi Bioscience Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by ABL Bio Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Acepodia Biotech Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Adicet Bio Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Aevi Genomic Medicine Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Allife Medical Science and Technology Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Allogene Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Altor Bioscience LLC, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Ambrx Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Arcellx Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Ascenta Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Ascentage Pharma Group International, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Asclepius Technology Company Group Suzhou Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Auransa Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Autolus Therapeutics Plc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Bantam Pharmaceutical LLC, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Beijing Immunochina Medical Science & Technology Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Beijing Sunbio Biotech Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by BioLineRx Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Biomunex Pharmaceuticals, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Biosion Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by BioVec Pharma Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by BiVictriX Therapeutics Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Boryung ViGenCell Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Co, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by CanBas Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by CARsgen Therapeutics Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Cartesian Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by CASI Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by CellCentric Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Collectar Biosciences Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Collectis SA, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Cellestia Biotech AG, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Cello Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Cellular Biomedicine Group Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Celularity Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Centrax International Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Checkpoint Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by ChemioCare USA Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Chipscreen Biosciences Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by CiMaas BV, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Constellation Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by CRISPR Therapeutics AG, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Curocell Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Cyteir Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Cytonus Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by DeuteRx LLC, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Diverse Biotech Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Co, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by EpicentRx Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Epizyme Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by eTheRNA Immunotherapies NV, H2

2019

Multiple Myeloma (Kahler Disease) - Pipeline by EUSA Pharma (UK) Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by ExCellThera Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Fate Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Fera Pharmaceuticals LLC, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Fortis Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Gadeta BV, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Galileo Research srl, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by GEMoaB Monoclonals GmbH, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by GemoPharm, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science srl, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Genentech Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Genmab A/S, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Gilead Sciences Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Glycostem Therapeutics BV, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by GlyTR Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by GP Pharm SA, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Gracell Bio, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by GT Biopharma Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by HaemaLogix Pty Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Harbour BioMed, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Harpoon Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Hebei Senlang Biotechnology Inc Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma AG, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Helix BioPharma Corp, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Helocyte Biosciences Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Hengenix Biotech Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Hillstream BioPharma Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Hinova Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by HitGen LTD, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by HRAIN Biotechnology Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by HuniLife Biotechnology Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Hutchison MediPharma Ltd, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by iCell Gene Therapeutics LLC, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Icenix Pharmaceuticals Ltd, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Ichnos Sciences Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by IDAC Theranostics Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by IDP Discovery Pharma SL, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology LLC, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by IGM Biosciences Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by ImmuneTarget Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Immunotech Biopharm Ltd, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Incuron LLC, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corp, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Indapta Therapeutics Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Ltd, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Inmune Bio Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Innovative Cellular Therapeutics Co Ltd, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Intra-Immug Pvt Ltd, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Inven2 AS, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by IO Biotech ApS, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Ionova Life Science Co Ltd, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Istesso Ltd, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Iterion Therapeutics, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Janpix Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by JN Biosciences LLC, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by JSK Therapeutics Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Jubilant Biosys Ltd, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Juno Pharmaceuticals Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Juno Therapeutics Inc, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Juventas Cell Therapy Ltd, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corp, H2 2019
Multiple Myeloma (Kahler Disease) - Pipeline by Kangpu Biopharmaceuticals Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Kiadis Pharma NV, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Kleo Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Klyss Biotech Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Komipharm International Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Kymab Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Leadiant Biosciences Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Les Laboratoires Servier SAS, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Leukogene Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Ligand Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Lokon Pharma AB, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Luye Pharma Group Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Machavert Pharmaceuticals LLC, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Marker Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Max Biopharma Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by MediGene AG, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by MedPacto Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Merck KGaA, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Miltenyi Biotec GmbH, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax LLC, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Modulation Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Momenta Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Mustang Bio Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing Bioheng Biotech Co Ltd, H2 2019

- Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing CART Medical Technology Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing Iaso Biotherapeutics Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing Legend Biotech Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by NantKwest Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by NBE-Therapeutics AG, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Nektar Therapeutics, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Neonc Technologies Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by NexImmune Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Northlake International LLC, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Oncoceutics Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by OncoFusion Therapeutics Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Oncology Venture A/S, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by OncoPep Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by OncoTartis Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by OncoTherapy Science Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by One World Cannabis Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Otsuka Pharmaceutical Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Peptron Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by PersonGen Anke Cellular Therapeutics Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by PersonGen Biomedicine Suzhou Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar SA, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Phosplatin Therapeutics LLC, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by PI Therapeutics Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Pimera Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Poseida Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Precision Biosciences Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Progenra Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Quadriga BioSciences Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Qwixel Therapeutics LLC, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Rainier Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Rapa Therapeutics LLC, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals SA, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Samus Therapeutics LLC, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Senity Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by SELLAS Life Sciences Group Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Bioray Laboratory Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Theorion Pharmaceutical Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Shenogen Pharma Group Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Shuttle Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by SignalRx Pharmaceuticals Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by SignPath Pharma Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by SpecificiT Pharma Inc, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pte Ltd, H2 2019

Multiple Myeloma (Kahler Disease) - Pipeline by SpringWorks Therapeutics Inc, H2 2019

- Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Sunomix Therapeutics, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by T-Knife GmbH, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by TaiGen Biotechnology Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Tiziana Life Sciences Plc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Tmunity Therapeutics Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Tolero Pharmaceuticals Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Triumvira Immunologics Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Ube Industries Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Unum Therapeutics Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Visterra Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Vycellix Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by WindMIL Therapeutics Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan YZY Biopharma Co Ltd, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by XEME BioPharma Inc, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Xiangxue Life Sciences, H2 2019
- Multiple Myeloma (Kahler Disease) - Pipeline by Zovis Pharmaceuticals, H2 2019
- Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2019

Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

COMPANIES MENTIONED

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

Aadi Bioscience Inc

AbbVie Inc

ABL Bio Inc

Acepodia Biotech Inc

Actinium Pharmaceuticals Inc

Active Biotech AB

Adicet Bio Inc

Aduro BioTech Inc

Aeglea BioTherapeutics Inc

Aevi Genomic Medicine Inc

Affimed GmbH

AIMM Therapeutics BV

Allife Medical Science and Technology Co Ltd

Allogene Therapeutics Inc

Altor Bioscience LLC

Ambrx Inc

Amgen Inc

Anhui Anke Biotechnology (Group) Co Ltd

APIM Therapeutics AS
APO-T BV
Arcellx Inc
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Asclepius Technology Company Group Suzhou Co Ltd
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Atara Biotherapeutics Inc
Auransa Inc
Aurigene Discovery Technologies Ltd
Autolus Therapeutics Plc
Bantam Pharmaceutical LLC
Bayer AG
Beijing Immunochina Medical Science & Technology Co Ltd
Beijing Sunbio Biotech Co Ltd
Betta Pharmaceuticals Co Ltd
BeyondSpring Inc
BioLineRx Ltd
Biomunex Pharmaceuticals
Biosion Inc
Biotest AG
BioVec Pharma Inc
BiVictriX Therapeutics Ltd
Boryung ViGenCell Inc
Boston Biomedical Inc
Bristol-Myers Squibb Co
CanBas Co Ltd
CARsgen Therapeutics Ltd
Cartesian Therapeutics Inc
CASI Pharmaceuticals Inc
Celgene Corp
Cell Source Inc
CellCentric Ltd
Cellecstar Biosciences Inc
Cellestis SA
Celleron Therapeutics Ltd
Cellestia Biotech AG
Cello Therapeutics Inc

CellProtect Nordic Pharmaceuticals AB
Cellular Biomedicine Group Inc
Celularity Inc
Celyad SA
Centrax International Inc
Checkpoint Therapeutics Inc
ChemioCare USA Inc
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp
CiMaas BV
Cleave Therapeutics Inc
Constellation Pharmaceuticals Inc
CRISPR Therapeutics AG
CStone Pharmaceuticals Co Ltd
Curis Inc
Curocell Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Cytonus Therapeutics Inc
Daiichi Sankyo Co Ltd
DC Prime BV
DeuteRx LLC
Diverse Biotech Inc
Eli Lilly and Co
Enceladus Pharmaceuticals BV
EpicentRx Inc
Epizyme Inc
eTheRNA Immunotherapies NV
EUSA Pharma (UK) Ltd
ExCellThera Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fera Pharmaceuticals LLC
Fortis Therapeutics Inc
Gadeta BV
Galileo Research srl
Gamida Cell Ltd
GEMoB Monoclonals GmbH

GemoPharm
Genenta Science srl
Genentech Inc
Genmab A/S
Gilead Sciences Inc
GlaxoSmithKline Plc
Gliknik Inc
GlycoMimetics Inc
Glycostem Therapeutics BV
GlyTR Therapeutics Inc
GP Pharm SA
Gracell Bio
GT Biopharma Inc
HaemaLogix Pty Ltd
Harbour BioMed
Harpoon Therapeutics Inc
Hebei Senlang Biotechnology Inc Ltd
Heidelberg Pharma AG
Helix BioPharma Corp
Helocyte Biosciences Inc
Hengenix Biotech Inc
Hillstream BioPharma Inc
Hinova Pharmaceuticals Inc
HitGen LTD
HRAIN Biotechnology Co Ltd
HuniLife Biotechnology Inc
Hutchison MediPharma Ltd
iCell Gene Therapeutics LLC
Iceni Pharmaceuticals Ltd
Ichnos Sciences Inc
IDAC Theranostics Inc
IDP Discovery Pharma SL
IGF Oncology LLC
IGM Biosciences Inc
ImmuneTarget Inc
Immunomedics Inc
Immunotech Biopharm Ltd
Incuron LLC
Incyte Corp

Indapta Therapeutics Inc
Inflection Biosciences Ltd
Immune Bio Inc
Innovative Cellular Therapeutics Co Ltd
Intra-Immug Pvt Ltd
Inven2 AS
Inventiva
IO Biotech ApS
Ionova Life Science Co Ltd
Istesso Ltd
Iterion Therapeutics
Janpix Inc
Jiangsu Hengrui Medicine Co Ltd
JN Biosciences LLC
Johnson & Johnson
JSK Therapeutics Inc
Jubilant Biosys Ltd
Juno Pharmaceuticals Inc
Juno Therapeutics Inc
Juventas Cell Therapy Ltd
JW Pharmaceutical Corp
Kangpu Biopharmaceuticals Ltd
Karyopharm Therapeutics Inc
Kiadis Pharma NV
Kleo Pharmaceuticals Inc
Klyss Biotech Inc
Komipharm International Co Ltd
Kymab Ltd
Laekna Therapeutics Shanghai Co Ltd
Leadiant Biosciences Inc
Les Laboratoires Servier SAS
Leukogene Therapeutics Inc
Ligand Pharmaceuticals Inc
Lokon Pharma AB
Luye Pharma Group Ltd
Machavert Pharmaceuticals LLC
Marker Therapeutics Inc
Max Biopharma Inc
MediGene AG

MedPacto Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biotec GmbH
MimiVax LLC
Modulation Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
MolMed SpA
Momenta Pharmaceuticals Inc
MorphoSys AG
Mustang Bio Inc
Nanjing Bioheng Biotech Co Ltd
Nanjing CART Medical Technology Co Ltd
Nanjing Iaso Biotherapeutics Co Ltd
Nanjing Legend Biotech Co Ltd
NantKwest Inc
NBE-Therapeutics AG
Nektar Therapeutics
Neonc Technologies Inc
NexImmune Inc
Nippon Kayaku Co Ltd
Northlake International LLC
Novartis AG
Noxxon Pharma AG
Oncoceutics Inc
Oncodesign SA
OncoFusion Therapeutics Inc
Oncology Venture A/S
Oncolytics Biotech Inc
Onconova Therapeutics Inc
OncoPep Inc
Oncopeptides AB
OncoTartis Inc
OncoTherapy Science Inc
One World Cannabis Ltd
Ono Pharmaceutical Co Ltd
Otsuka Pharmaceutical Co Ltd

Peptron Inc
PersonGen Anke Cellular Therapeutics Co Ltd
PersonGen Biomedicine Suzhou Co Ltd
Pfizer Inc
Pharma Mar SA
Phosplatin Therapeutics LLC
PI Therapeutics Ltd
Pimera Inc
Poseida Therapeutics Inc
Precision Biosciences Inc
Prescient Therapeutics Ltd
Progenra Inc
Quadriga BioSciences Inc
Qwixel Therapeutics LLC
Rainier Therapeutics Inc
Rapa Therapeutics LLC
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Samus Therapeutics LLC
Sanofi
Seattle Genetics Inc
Selenity Therapeutics Inc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
Shanghai Bioray Laboratory Inc
Shanghai Theorion Pharmaceutical Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shenogen Pharma Group Ltd
Shuttle Pharmaceuticals Inc
Sichuan Kelun Pharmaceutical Co Ltd
SignalRx Pharmaceuticals Inc
SignPath Pharma Inc

I would like to order

Product name: Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/M95396F7824EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M95396F7824EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970